Novo Nordisk is seeking FDA approval for a 7.2 mg dose of Wegovy, nearly three times the current maximum dose. The application is under expedited FDA review, with a decision expected within one to two ...

Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National Priority Voucher (CNPV) program on a higher-dose version of its obesity med ...

Novo Nordisk said a weight-loss drug candidate helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company. The Danish ...

Amycretin targets GLP-1 and amylin hormones, seen as potential best-in-class therapy Novo shares rise over 5% after amycretin trial results Amycretin aids significant weight loss and glucose control ...

The studies were a setback for the optimistic view that semaglutide and other drugs used in obesity and diabetes treatment could help prevent a number of brain diseases. By Gina Kolata Gina Kolata has ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression of Alzheimer’s disease in closely watched trials, drugmaker Novo Nordisk ...

Novo Nordisk said on Monday an older oral version of its semaglutide drug failed to meet its main goal in late-stage trials testing whether the medicine can slow cognitive decline in Alzheimer’s ...

Novo Nordisk's semaglutide fails in Alzheimer's trials Trials aimed for 20% slowing of cognitive decline in Alzheimer's More details to be released at December 3 meeting COPENHAGEN, Nov 24 (Reuters) - ...

MMO Players are piling in to the Guild Wars remaster, and it's giving the servers trouble: 'Demand for Guild Wars Reforged blew past our projections' MMO FF14's Yoshi-P reveals why he's finally ...

Novo has experienced a prolonged sell.off over the last months, declining more than 65% from all-time highs. Why some kind of pessimism is justified, the current market cap is way to low considering ...

A Novo Nordisk challenge has driven a Pennsylvania-based telehealth company to voluntarily discontinue compounded semaglutide product claims, adding to the Danish drugmaker’s string of wins against ...